Sale

Scleroderma Therapeutics Market

Global Scleroderma Therapeutics Market Share, Size, Analysis: By Drug Class: Immunosuppressors, Phosphodiesterase 5 Inhibitors - PHA, Endothelin Receptor Antagonists, Prostacyclin Analogues, Calcium Channel Blockers, Analgesics, Others; By Indication; By Treatment Type; By End User; Regional Analysis; Competitive Landscape; 2024-2032

Global Scleroderma Therapeutics Market Outlook

The value of the global scleroderma therapeutics market was USD 2.04 billion in 2023, driven by increasing prevalence of scleroderma, rising awareness about the disease across the globe. The market is expected to grow at a CAGR of 6.20% during the forecast period of 2024-2032 to reach value of USD 3.50 billion by 2032.

 

Scleroderma Therapeutics Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Properties and Applications

Scleroderma refers to an autoimmune condition that affects the skin, vessels of the blood, muscles, and internal organs. Usually, the disease is caused by an abnormal immune response. Immunosuppressive medicines and, in some cases, glucocorticoids are included to treat this condition.

 

Scleroderma Therapeutics Market Drug Class

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF


The drug class available in the industry can be divided into:

  • Immunosuppressors
  • Phosphodiesterase 5 Inhibitors - PHA 
  • Endothelin Receptor Antagonists
  • Prostacyclin Analogues
  • Calcium Channel Blockers
  • Analgesics
  • Others

Based on indication, the scleroderma therapeutics market can be divided into:

  • Systemic
  • Localized

The EMR report looks into the regional markets of scleroderma therapeutics like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

 

Scleroderma Therapeutics Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis

The demand in the industry is mainly being driven by the use of off-label medications approved. The lack of curative drugs and a higher prevalence of off-label drug use are the underlying factors that drive interest in markets for rare diseases. The advancement of targeted biologics, as well as small molecular combination therapies, are expected to be supported in the industry. The market is also projected to be supported by the rising prevalence of scleroderma and the increasing incidences of genetic mutations combined with dramatic changes in the environment. The rising disposable incomes, allowing greater expenditure, and the existence of a well-defined regulatory framework that promotes successful therapy production in developed regions are driving the growth of the industry.

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global scleroderma therapeutics market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • F. Hoffman La Roche Ltd.
  • Boehringer Ingelheim International GmbH
  • arGentis™ Pharmaceuticals, LLS
  • Kadmon Holdings, Inc.
  • Emerald Health Pharmaceuticals. Inc.
  • Others

The EMR report gives an in-depth insight into the scleroderma therapeutics market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Class
  • Indication
  • Treatment Type
  • End User
  • Region
Breakup by Drug Class
  • Immunosuppressors
  • Phosphodiesterase 5 Inhibitors - PHA
  • Endothelin Receptor Antagonists
  • Prostacyclin Analogues
  • Calcium Channel Blockers
  • Analgesics
  • Others
Breakup by Indication
  • Systemic
  • Localized
Breakup by Treatment Type
  • Drug Treatment
  • Surgical Treatment
  • Therapy
Breakup by End User
  • Hospitals & Clinics
  • Homecare Settings
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • F. Hoffman-La Roche Ltd.
  • Boehringer Ingelheim International GmbH
  • arGentis™ Pharmaceuticals, LLS
  • Kadmon Holdings, Inc.
  • Emerald Health Pharmaceuticals Inc.
  • EuBiologics Co., Ltd.
  • Astellas Pharma Inc.
  • Sanofi
  • Allergan
  • Novartis AG
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope
    1.4    Research Methodology
2    Executive Summary
3    Scleroderma Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Scleroderma Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Scleroderma Epidemiology (2016-2031)
    5.3    Europe Scleroderma Epidemiology (2016-2031)
    5.4    Asia-Pacific Scleroderma Epidemiology (2016-2031)
    5.5    Latin America Scleroderma Epidemiology (2016-2031)
    5.6    Middle East & Africa Scleroderma Epidemiology (2016-2031)
6    Global Scleroderma Therapeutics Market Overview
    6.1    Global Scleroderma Therapeutics Market Historical Value (2017-2023)
    6.2    Global Scleroderma Therapeutics Market Forecast Value (2024-2032)
7    Global Scleroderma Therapeutics Market Landscape
    7.1    Scleroderma Therapeutics: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Scleroderma Therapeutics: Product Landscape
        7.2.1    Analysis by Drug Class
        7.2.2    Analysis by Indication
        7.2.3    Analysis by Treatment Type
        7.2.4    Analysis by End User
8    Scleroderma Therapeutics Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Scleroderma Therapeutics Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Global Scleroderma Therapeutics Market Segmentation
    11.1    Global Scleroderma Therapeutics Market by Drug Class
        11.1.1    Market Overview
        11.1.2    Immunosuppressors
        11.1.3    Phosphodiesterase 5 Inhibitors - PHA 
        11.1.4    Endothelin Receptor Antagonists
        11.1.5    Prostacyclin Analogues
        11.1.6    Calcium Channel Blockers
        11.1.7    Analgesics
        11.1.8    Others
    11.2    Global Scleroderma Therapeutics Market by Indication
        11.2.1    Market Overview
        11.2.2    Systemic
        11.2.3    Localized
    11.3    Global Scleroderma Therapeutics Market by Treatment Type
        11.3.1    Market Overview
        11.3.2    Drug Treatment
        11.3.3    Surgical Treatment
        11.3.4    Therapy
    11.4    Global Scleroderma Therapeutics Market by End User
        11.4.1    Market Overview
        11.4.2    Hospitals & Clinics
        11.4.3    Homecare Settings
        11.4.4    Others
    11.5    Global Scleroderma Therapeutics Market by Region
        11.5.1    Market Overview
        11.5.2    North America
        11.5.3    Europe 
        11.5.4    Asia Pacific
        11.5.5    Latin America
        11.5.6    Middle East and Africa
12    North America Scleroderma Therapeutics Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Scleroderma Therapeutics Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Scleroderma Therapeutics Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Scleroderma Therapeutics Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Scleroderma Therapeutics Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation 
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization 
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Partnership and Collaborations Analysis
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    F. Hoffman-La Roche Ltd.
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Boehringer Ingelheim International GmbH
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    arGentis™ Pharmaceuticals, LLS
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    Kadmon Holdings, Inc.
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    Emerald Health Pharmaceuticals Inc.
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    EuBiologics Co., Ltd.
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Astellas Pharma Inc.
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Sanofi
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Allergan
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    Novartis AG
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
    23.11    Bristol-Myers Squibb Company
        23.11.1    Financial Analysis
        23.11.2    Product Portfolio
        23.11.3    Demographic Reach and Achievements
        23.11.4    Mergers and Acquisitions
        23.11.5    Certifications
    23.12    GlaxoSmithKline plc.
        23.12.1    Financial Analysis
        23.12.2    Product Portfolio
        23.12.3    Demographic Reach and Achievements
        23.12.4    Mergers and Acquisitions
        23.12.5    Certifications
24    Scleroderma Therapeutics - Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

In 2023, the global scleroderma therapeutics market attained a value of nearly USD 2.04 billion.

The market is projected to grow at a CAGR of 6.20% between 2024 and 2032.

The market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach USD 3.50 billion by 2032.

The major industry drivers include rising population, advancement of targeted biologics, and small molecular combination therapies and the use of off-label medications approved.

The key industry trends driving growth include the rising prevalence of scleroderma and the increasing incidences of genetic mutations combined with dramatic changes in the environment.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The significant drug classes available are immunosuppressors, phosphodiesterase 5 inhibitors – PHA, endothelin receptor antagonists, prostacyclin analogues, calcium channel blockers and analgesics, among others.

The leading indication types of the industry are systemic and localized.

The major players in the industry are F. Hoffman-La Roche Ltd., Boehringer Ingelheim International GmbH, arGentis™ Pharmaceuticals, LLS, Kadmon Holdings, Inc., Emerald Health, Pharmaceuticals Inc., among others.

 

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER